Page 2 - Ben Comer News Today

Verve Therapeutics’ co-founder and CEO Sekar Kathiresan offers insight into how he launched a gene editing drug company and dosed the first...

In an exclusive interview, FDA’s Peter Marks discusses CBER priorities, PDUFA VII funding, and improving the dialogue between regulators and...

Additional executive responses to our 2023 manufacturing and supply chain outlook questions.


Additional experts weigh in on Life Science Leader's 2023 finance and funding outlook questions.


Biopharma executives offer options, tips and strategies for navigating finance and funding challenges in 2023.


In this Q&A, 10 executives provide their thoughts on what the future holds for biopharmaceutical manufacturing and supply chain operations, and...

Creativity will be in high demand, not just to control costs during tough economic conditions, but in key functional areas like business development...

Our experts talk about everything from alternative financing arrangements to investment trends that biopharma execs should keep their eyes on.


This article is part two of a two-part series covering the highlights of the Galien Forum. Part 1 can be accessed here.


The CEO Of Aristea talks about the company’s unusual move to do both a series B round, but not as a crossover, while also making a deal with...